Retension Pharmaceuticals Revenue and Competitors
Employee Data
- Retension Pharmaceuticals has 7 Employees.
- Retension Pharmaceuticals grew their employee count by 40% last year.
Retension Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|
Retension Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $10.1M | 48 | -9% | N/A | N/A |
#10 | $16.1M | 88 | 4% | N/A | N/A |
What Is Retension Pharmaceuticals?
Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension. RTN-001 has been evaluated in over 265 subjects across 9 clinical trials. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension. RTN-001 is a second generation PDE5i that preferentially distributes to cardiovascular tissues, where it acts to mediate a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension.
keywords:N/A
N/A
Total Funding
7
Number of Employees
N/A
Revenue (est)
40%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.7M | 7 | 40% | N/A |
#2 | $0.1M | 7 | 0% | $6.1M |
#3 | $3.5M | 7 | -30% | N/A |
#4 | $1.4M | 7 | -36% | N/A |
#5 | $0.5M | 7 | N/A | N/A |